Association between diabetes, diabetes treatment and risk of developing endometrial cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence suggests that diabetes is a risk factor for endometrial cancer incidence. However, most of these studies used case-control study designs and did not adjust for obesity, an established risk factor for endometrial cancer. In addition, few epidemiological studies have examined the association between diabetes treatment and endometrial cancer risk. The objective of this study was to assess the relationships among diabetes, diabetes treatment and endometrial cancer risk in postmenopausal women participating in the Women's Health Initiative (WHI). METHODS: A total of 88 107 postmenopausal women aged 50-79 years who were free of cancer and had no hysterectomy at baseline were followed until date of endometrial cancer diagnosis, death, hysterectomy or loss to follow-up, whichever came first. Endometrial cancers were confirmed by central medical record and pathology report review. Multivariate Cox proportional hazards regression models were used to estimate hazard ratios (HRs) (95% confidence interval (CI)) for diagnosis of diabetes and metformin treatment as risk factors for endometrial cancer. RESULTS: Over a mean of 11 years of follow-up, 1241 endometrial cancers developed. In the primary analysis that focused on prevalent diabetes at enrolment, compared with women without diabetes, women with self-reported diabetes, and the subset of women with treated diabetes, had significantly higher risk of endometrial cancer without adjusting for BMI (HR=1.44, 95% CI: 1.13-1.85 for diabetes, HR=1.57, 95% CI: 1.19-2.07 for treated diabetes). However after adjusting for BMI, the associations between diabetes, diabetes treatment, diabetes duration and the risk of endometrial cancer became non-significant. Elevated risk was noted when considering combining diabetes diagnosed at baseline and during follow-up as time-dependent exposure (HR=1.31, 95% CI: 1.08-1.59) even after adjusting for BMI. No significant association was observed between metformin use and endometrial cancer risk. CONCLUSIONS: Our results suggest that the relationship observed in previous research between diabetes and endometrial cancer incidence may be largely confounded by body weight, although some modest independent elevated risk remains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Evidence from epidemiologic, clinical and experimental research has suggested that metformin may have potential anticancer effects (Evans et al, 2005; Buzzai et al, 2007; Ben Sahra et al, 2008; Decensi et al, 2010; Noto et al, 2012).”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“AMPK activation inhibits cellular proliferation and mRNA translation via mammalian target of rapamycin (mTOR) signalling, which may contribute to the direct anti-neoplastic effects of metformin (Shaw et al, 2005; Zakikhani et al, 2006; Williams and Brenman, 2008).”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“Evidence from epidemiologic, clinical and experimental research has suggested that metformin may have potential anticancer effects (Evans et al, 2005; Buzzai et al, 2007; Ben Sahra et al, 2008; Decensi et al, 2010; Noto et al, 2012).”
BackgroundCancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 1×
“Evidence from epidemiologic, clinical and experimental research has suggested that metformin may have potential anticancer effects (Evans et al, 2005; Buzzai et al, 2007; Ben Sahra et al, 2008; Decensi et al, 2010; Noto et al, 2012).”
BackgroundBody mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0832 · Cited by 321 · cited 4×
“This hypothesis has been supported by epidemiologic studies showing that an increased risk of endometrial cancer is associated with use of unopposed exogenous estrogens (Smith et al, 1975; Ziel and Finkle, 1975; Grady et al, 1995; Crosbie et al, 2010).”
BackgroundMethodInfluentialDiabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors
Saltzman, B. S., Doherty, J. A., Hill, D. A., Beresford, S. A., Voigt, L. F., Chen, C., & Weiss, N. S. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm333 · Cited by 102
Self-citation
Cited by
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Harding, J. L., Shaw, J. E., Peeters, A., Cartensen, B., & Magliano, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1996 · Cited by 286
Metadata
- Authors
- Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., Regier, M., Wactawski-Wende, J., & Margolis, K. L.
- Venue
- British Journal of Cancer
- Published
- 2014-07-22
- Volume
- 111
- Issue
- 7
- Pages
- 1432-1439
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1972894305
- Cited by
- 126
- References
- 9
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between diabetes, diabetes treatment and risk of developing endometrial cancer. https://app.cochat.ai/papers/10.1038/bjc.2014.407
- The paper
- Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., Regier, M., Wactawski-Wende, J., & Margolis, K. L. (2014). Association between diabetes, diabetes treatment and risk of developing endometrial cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2014.407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.